Renaissance Technologies (RenTech)'s NAGE Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 659,584 shares of Niagen Bioscience, Inc. (NAGE) worth $2.1 M, representing 0.00% of the portfolio. First purchased in 2017-Q4, this long-term strategic position has been held for 27 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in NAGE, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 414,725 shares. Largest reduction occurred in Q2 2026, reducing 669,259 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Niagen Bioscience (NAGE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Niagen Bioscience (NAGE) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -669,259 | Reduce 50.36% | 659,584 | $3.19 |
| Q1 2026 | +414,725 | Add 45.37% | 1.33 M | $4.41 |
| Q4 2025 | +201,118 | Add 28.21% | 914,118 | $6.36 |
| Q3 2025 | +223,400 | Add 45.63% | 713,000 | $9.33 |
| Q2 2025 | -33,500 | Reduce 6.40% | 489,600 | $14.41 |
| Q1 2025 | -189,688 | Reduce 26.61% | 523,100 | $6.90 |
| Q4 2024 | +288,588 | Add 68.03% | 712,788 | $5.30 |
| Q3 2024 | +8,100 | Add 1.95% | 424,200 | $3.65 |
| Q2 2024 | +32,400 | Add 8.44% | 416,100 | $2.73 |
| Q1 2024 | -85,602 | Reduce 18.24% | 383,700 | $3.48 |
| Q4 2023 | +24,390 | Add 5.48% | 469,302 | $1.43 |
| Q3 2023 | -15,627 | Reduce 3.39% | 444,912 | $1.46 |
| Q2 2023 | +33,339 | Add 7.80% | 460,539 | $0.00 |
| Q1 2023 | -143,700 | Reduce 25.17% | 427,200 | $0.00 |
| Q4 2022 | -47,310 | Reduce 7.65% | 570,900 | $0.00 |
| Q3 2022 | -121,690 | Reduce 16.45% | 618,210 | $1.23 |
| Q2 2022 | +319,399 | Add 75.96% | 739,900 | $1.67 |
| Q1 2022 | +382,413 | Add 1004.02% | 420,501 | $2.46 |
| Q4 2021 | +38,088 | New Buy | 38,088 | $3.73 |
| Q1 2021 | -235,200 | Sold Out | 0 | $0.00 |
| Q4 2020 | +153,819 | Add 189.01% | 235,200 | $4.80 |
| Q3 2020 | -128,819 | Reduce 61.28% | 81,381 | $4.01 |
| Q2 2020 | +210,200 | New Buy | 210,200 | $4.59 |
| Q4 2019 | -39,900 | Sold Out | 0 | $0.00 |
| Q3 2019 | +39,900 | New Buy | 39,900 | $3.93 |
| Q1 2018 | -45,100 | Sold Out | 0 | $0.00 |
| Q4 2017 | +45,100 | New Buy | 45,100 | $5.88 |
Renaissance Technologies (RenTech)'s Niagen Bioscience Investment FAQs
Renaissance Technologies (RenTech) first purchased Niagen Bioscience, Inc. (NAGE) in Q4 2017, acquiring 45,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Niagen Bioscience, Inc. (NAGE) for 27 quarters since Q4 2017.
Renaissance Technologies (RenTech)'s largest addition to Niagen Bioscience, Inc. (NAGE) was in Q1 2026, adding 1,328,843 shares worth $5.86 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 659,584 shares of Niagen Bioscience, Inc. (NAGE), valued at approximately $2.1 M.
As of the Q2 2026 filing, Niagen Bioscience, Inc. (NAGE) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Niagen Bioscience, Inc. (NAGE) was 1,328,843 shares, as reported at the end of Q1 2026.